Evolus, Inc.
Evolus, Inc. (EOLS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EOLS · as of Jun 8, 2026
Key Statistics
Explore Evolus, Inc. Data
eols stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 84.6%
The EOLS analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $15.00, representing +122.39% upside from the current price of $6.75.
Competitors & Peers
eols competitorsEOLS
AUTL
CBLL
EHAB
KIDS
KMDAStock Performance
Full HistoryAbout Evolus, Inc.
Evolus, Inc. a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulin…
what is evolus, inc. · eols stock overview · evolus, inc. company profile · who is evolus, inc. ceo · eols NASDAQ · evolus, inc. headquarters · evolus, inc. business segments
About Stock Overview & Key Data
Evolus, Inc. (EOLS) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Feb 8, 2018. As of the latest trading session, EOLS stock price is $6.75, with a market capitalization of $445.5M. The stock has returned -29.90% over the past 12 months and +1.73% year-to-date.
According to 13 Wall Street analysts, the consensus rating for Evolus, Inc. stock is Buy, with an average 12-month price target of $15.00. In fiscal year 2025, Evolus, Inc. reported revenue of $297.2M and net income of -$51.6M. For detailed data — including Evolus, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Evolus, Inc. (EOLS) stock price is $6.75. The stock is traded on NASDAQ under the ticker symbol EOLS. The 52-week range is $3.86 – $10.62.